Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] NSAIDs for high-risk patients: none, celecoxib, or naproxen?

Godot-like, the all-round safe and effective oral anti-inflammatory drug is awaited. Meantime, substantial effort is devoted to discovering how the existing imperfect non-steroidal anti-inflammatory drugs (NSAIDs) might be best used—balancing the need for effective analgesia with their multiple risks. The randomised controlled trial by Francis Chan and colleagues1 reported in The Lancet investigated two of these NSAIDs that have been seen as the best (or least worst) in the cardiovascular safety stakes, celecoxib and naproxen.

email